Kidney cancer biomarker predicts disease risk and survival
from Genetic Engineering & Biotechnology News
Validated diagnostic markers are key to the early detection and treatment of cancer. Moreover, if these biomarkers can be readily extracted and detected in bodily fluids, a simple, clinical diagnostic test can be developed that would be of extreme value to patients and physicians. For kidney cancer, investigators at Brigham and Women's Hospital and Beth-Israel Deaconess Medical Center believe they have found such a biomarker. In a new study, the researchers showed that kidney-injury-molecule-1 — which can be detected in the urine and blood — substantially helped distinguish between those who went on to develop kidney cancer from those who did not.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063